AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23829946 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 880
Study 22768174 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (VAL, 320 mg/d)
Number of subjects: 38
Study 22768174 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 38
Study 19180484 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitins 4 and 6 sulfate (CS) 800 mg once daily for 2 years
Number of subjects: 622
Study 19180484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study 19180484 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitins 4 and 6 sulfate (CS)
Number of subjects: 622
Study 17410467 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg t.i.d.) with ibuprofen (1800 mg/day)
Number of subjects: 20
Study 17410467 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ibuprofen (1800 mg/day)
Number of subjects: 20
Study 17410467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 15179130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapy
Number of subjects: 40
Study 15179130 — intervention group
Group type: COMPARATOR
Intervention: Standard care (reference group)
Number of subjects: 40
Study 11490212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral PGE2 gel (1 mg)
Number of subjects: 22
Study 11490212 — intervention group
Group type: COMPARATOR
Intervention: Intracavernous papaverine (60 mg)
Number of subjects: 22
Study 11490212 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 22
Study 8991296 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 8991296 — intervention group
Group type: COMPARATOR
Intervention: Control (no hypnosis, context reinstatement, or motivational instructions)
Number of subjects: 0
Study 8991296 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 0
Study 11767426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 100 mg
Number of subjects: 80
Study 11767426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 100 mg and cimetidine 400 mg
Number of subjects: 80
Study 11767426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 100 mg and effervescent cimetidine (cimetidine 200 mg + sodium citrate 1.8 g)
Number of subjects: 80
Study 11767426 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent cimetidine orally in 30 ml of water 5 min before anaesthetic induction
Number of subjects: 80
Study 11767426 — intervention group
Group type: COMPARATOR
Intervention: Control group (Hydroxyzine 100 mg)
Number of subjects: 80
Study 11767426 — intervention group
Group type: COMPARATOR
Intervention: Control group (Hydroxyzine 100 mg and cimetidine 400 mg)
Number of subjects: 80
Study 11767426 — intervention group
Group type: COMPARATOR
Intervention: Control group (Hydroxyzine 100 mg and effervescent cimetidine)
Number of subjects: 80
Study 3440226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg
Number of subjects: 71
Study 3440226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 20 mg
Number of subjects: 71
Study 3440226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 30 mg
Number of subjects: 71
Study 3440226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 40 mg
Number of subjects: 71
Study 3440226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (30 mg or 40 mg)
Number of subjects: 71
Study 3440226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (all doses)
Number of subjects: 71
Study 3440226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (higher-than-conventional doses)
Number of subjects: 71
Study 29501358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse gender
Number of subjects: 400
Study 29501358 — intervention group
Group type: COMPARATOR
Intervention: Nurse race
Number of subjects: 400
Study 29501358 — intervention group
Group type: COMPARATOR
Intervention: Patient gender
Number of subjects: 400
Study 29501358 — intervention group
Group type: COMPARATOR
Intervention: Patient race
Number of subjects: 400
Study 27537084 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 235
Study 27537084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 23604252 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT) without fluorescein
Number of subjects: 200
Study 23604252 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT) with fluorescein
Number of subjects: 200
Study 22518026 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 779
Study 22518026 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 779
Study 20072816 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-min IOOV
Number of subjects: 200
Study 20072816 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min IOOV
Number of subjects: 200
Study 20072816 — intervention group
Group type: COMPARATOR
Intervention: 30-min education
Number of subjects: 200
Study 18728643 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-cisplatin (D 60 mg m(‐2) and P 80 mg m(‐2) on day 1, every 3-4 weeks)
Number of subjects: 80
Study 18728643 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel monotherapy (D 70 mg m(‐2), every 3 weeks)
Number of subjects: 80
Study 16760295 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI regimen (arm A)
Number of subjects: 81
Study 16760295 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus celecoxib 400 mg twice daily for 14 days (arm B)
Number of subjects: 81
Study 12648175 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 50 micro g of intravaginal misoprostol
Number of subjects: 104
Study 12648175 — intervention group
Group type: COMPARATOR
Intervention: Two consecutive doses of intravaginal 50 micro g misoprostol 6 h apart
Number of subjects: 104
Study 11526759 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (group B)
Number of subjects: 69
Study 11526759 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocoagulation (group A)
Number of subjects: 69
Study 11526759 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored methods of treatment (group C)
Number of subjects: 69
Study 9187067 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 138
Study 9187067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 8243430 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol beer with 0% alcohol (A)
Number of subjects: 10
Study 8243430 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcohol beer with 2.7% alcohol (B)
Number of subjects: 10
Study 8243430 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcohol beer with 5.4% alcohol (C)
Number of subjects: 10
Study 3798264 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Dormicum; Roche) 0.1 mg/kg
Number of subjects: 16
Study 3798264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31848786 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-trees model
Number of subjects: 155
Study 31848786 — intervention group
Group type: COMPARATOR
Intervention: Random forest model
Number of subjects: 155
Study 31848786 — intervention group
Group type: COMPARATOR
Intervention: Clinical measurements (average macular ganglion cell-inner plexiform layer thickness)
Number of subjects: 155
Study 31848786 — intervention group
Group type: COMPARATOR
Intervention: Clinical measurements (average circumpapillary retinal nerve fiber layer thickness)
Number of subjects: 155
Study 31050955 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation using PIPS with 17% EDTA and 5.25% NaOCl
Number of subjects: 56
Study 31050955 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigation with 5.25% sodium hypochlorite (NaOCl)
Number of subjects: 56
Study 28768327 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 223
Study 28768327 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Disorder Protocols (SDPs)
Number of subjects: 223
Study 28768327 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 223
Study 26184061 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Performance (KP) - auditory and kinaesthetic combined
Number of subjects: 36
Study 26184061 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of Results (KR)
Number of subjects: 36
Study 26184061 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinaesthetic KP
Number of subjects: 36
Study 26184061 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory KP
Number of subjects: 36
Study 22795722 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental maximal cycle exercise
Number of subjects: 20
Study 22795722 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation of the motor cortex
Number of subjects: 20
Study 21944697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification and stress reduction intervention (LG)
Number of subjects: 96
Study 21944697 — intervention group
Group type: COMPARATOR
Intervention: Written advice only (AG)
Number of subjects: 96
Study 19583930 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine combined with Songling Xuemaikang Capsule (SXC)
Number of subjects: 70
Study 19583930 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 70
Study 19583930 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine combined with SXC
Number of subjects: 70
Study 19583930 — intervention group
Group type: EXPERIMENTAL
Intervention: SXC
Number of subjects: 70
Study 19583930 — intervention group
Group type: COMPARATOR
Intervention: Routine group
Number of subjects: 70
Study 19583930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 17113893 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric Stimulation (ES)
Number of subjects: 68
Study 17113893 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (2.5 mg three times per day)
Number of subjects: 68
Study 17113893 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 68
Study 17113893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 14969611 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 988
Study 14969611 — intervention group
Group type: COMPARATOR
Intervention: Stent-assisted percutaneous coronary intervention (PCI)
Number of subjects: 988
Study 11482635 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐hr team-oriented training
Number of subjects: 260
Study 11482635 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐hr informational training
Number of subjects: 260
Study 11482635 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training groups
Number of subjects: 260
Study 11482635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 260
Study 9764338 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with DEC (6 mg/kg) and ivermectin (200 micrograms/kg)
Number of subjects: 31
Study 9764338 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with DEC (6 mg/kg) and ivermectin (400 micrograms/kg)
Number of subjects: 31
Study 9764338 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment with ivermectin (200 micrograms/kg) followed by DEC (6 mg/kg) after 5 days
Number of subjects: 31
Study 8311599 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative, nonpulsatile perfusion
Number of subjects: 60
Study 8311599 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative, pulsatile perfusion
Number of subjects: 60
Study 8311599 — intervention group
Group type: COMPARATOR
Intervention: No laxative, nonpulsatile perfusion
Number of subjects: 60
Study 8311599 — intervention group
Group type: EXPERIMENTAL
Intervention: No laxative, pulsatile perfusion
Number of subjects: 60
Study 3414920 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin 600 mg orally one hour before surgery
Number of subjects: 84
Study 3414920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.05 mg/kg before induction of anaesthesia
Number of subjects: 84
Study 3414920 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 84
Study 1500629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal beclomethasone dipropionate (Bdp) 336 micrograms/day
Number of subjects: 18
Study 1500629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 999409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (12.5 mg/70 kg, i.m.)
Number of subjects: 0
Study 999409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25 mg/70 kg, i.m.)
Number of subjects: 0
Study 999409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (25 mg/70 kg, i.m.)
Number of subjects: 0
Study 999409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (50 mg/70 kg, i.m.)
Number of subjects: 0
Study 999409 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (15 mg/70 kg, i.m.)
Number of subjects: 0
Study 999409 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (30 mg/70 kg, i.m.)
Number of subjects: 0
Study 999409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31738696 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior Restorative (FBF)
Number of subjects: 54
Study 31738696 — intervention group
Group type: EXPERIMENTAL
Intervention: Charisma Smart Composite (CSC)
Number of subjects: 54
Study 31738696 — intervention group
Group type: EXPERIMENTAL
Intervention: Equia Forte Fil (EF)
Number of subjects: 54
Study 31574878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous granisetron 3 mg every 8 hours for 4 days or until ICU discharge
Number of subjects: 154
Study 31574878 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (equal volume)
Number of subjects: 154
Study 27789297 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa treatment
Number of subjects: 0
Study 26427781 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on CAD/CAM module (32 students)
Number of subjects: 56
Study 26427781 — intervention group
Group type: COMPARATOR
Intervention: Video-supported lecture (Control group, 24 students)
Number of subjects: 56
Study 26427781 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-module questionnaire (48 students from both groups)
Number of subjects: 56
Study 23432682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-depletion condition (manipulated through watching a video requiring visual attention or completing an incongruent Stroop task)
Number of subjects: 0
Study 23432682 — intervention group
Group type: COMPARATOR
Intervention: Low-depletion condition (control group)
Number of subjects: 0
Study 21787825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via Dolphin™ device at 240, 480, and 690 μg doses
Number of subjects: 36
Study 21787825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via Dolphin™ device
Number of subjects: 36
Study 21787825 — intervention group
Group type: COMPARATOR
Intervention: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via pipette at 240 μg dose
Number of subjects: 36
Study 19659978 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational and skills training intervention alone
Number of subjects: 130
Study 19659978 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational and skills training intervention with partner assistance
Number of subjects: 130
Study 19659978 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients assisted by female partners
Number of subjects: 130
Study 19659978 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 130
Study 19659978 — intervention group
Group type: EXPERIMENTAL
Intervention: Older couples
Number of subjects: 130
Study 16430625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-basel periprostatic nerve block (PPNB)
Number of subjects: 143
Study 16430625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-apical periprostatic nerve block (PPNB)
Number of subjects: 143
Study 16430625 — intervention group
Group type: COMPARATOR
Intervention: Probe introduction
Number of subjects: 143
Study 14718713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of 1-octanol
Number of subjects: 12
Study 14718713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11434165 — intervention group
Group type: COMPARATOR
Intervention: Dietary antioxidants
Number of subjects: 36
Study 11434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low manganese intake
Number of subjects: 36
Study 11434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intake of antioxidant components (zinc, copper, manganese, vitamin E, vitamin C)
Number of subjects: 36
Study 10068731 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet (Group 1)
Number of subjects: 132
Study 10068731 — intervention group
Group type: COMPARATOR
Intervention: Clear liquids (Group 2)
Number of subjects: 132
Study 8299318 — intervention group
Group type: EXPERIMENTAL
Intervention: 349U85 hydrochloride (doses from 2 mg to 250 mg)
Number of subjects: 27
Study 8299318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8299318 — intervention group
Group type: EXPERIMENTAL
Intervention: 349U85 hydrochloride
Number of subjects: 27
Study 2847994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral delta‐9‐tetrahydrocannabinol (THC), 15 mg/m2
Number of subjects: 36
Study 2847994 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (PCZ), 10 mg
Number of subjects: 36
Study 31670603 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringenin 150 mg from an extract of whole oranges standardized to 28% naringenin, taken three times/day for 8 weeks
Number of subjects: 1
Study 31301434 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and irrigation with CUR solution (100 mg/L)
Number of subjects: 25
Study 31301434 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and LED irradiation (465-485 nm, 60 s)
Number of subjects: 25
Study 31301434 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP, irrigation with CUR solution (100 mg/L), and LED irradiation (465-485 nm, 60 s)
Number of subjects: 25
Study 31301434 — intervention group
Group type: COMPARATOR
Intervention: SRP (Control group)
Number of subjects: 25
Study 28764691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion TKA
Number of subjects: 56
Study 28764691 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 56
Study 28764691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 26615377 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental sodium 5mg/kg/IV
Number of subjects: 50
Study 26615377 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.01 mg/kg/IV and ketamine 1 mg/kg/IV
Number of subjects: 50
Study 24045663 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 0
Study 24045663 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 0
Study 21353655 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 second television commercial demonstrating behind-the-scenes techniques used to artificially enhance media models
Number of subjects: 87
Study 21353655 — intervention group
Group type: EXPERIMENTAL
Intervention: Music videos and ordinary television commercials
Number of subjects: 87
Study 21353655 — intervention group
Group type: COMPARATOR
Intervention: Television and commercials featuring no people (control group)
Number of subjects: 87
Study 18304147 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling/education session by an atopic dermatitis educator
Number of subjects: 151
Study 18304147 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 151
Study 17142334 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 34
Study 17142334 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid-etched technique with control adhesive (Transbond)
Number of subjects: 34
Study 12660676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation (VF)
Number of subjects: 15042
Study 12660676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia (VT)
Number of subjects: 15042
Study 12660676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VF and VT
Number of subjects: 15042
Study 12660676 — intervention group
Group type: COMPARATOR
Intervention: Neither VF nor VT
Number of subjects: 15042
Study 12660676 — intervention group
Group type: EXPERIMENTAL
Intervention: Late arrhythmias (>48 hours after enrollment)
Number of subjects: 15042
Study 11522187 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 vaccine
Number of subjects: 49
Study 11522187 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 vaccine with SF-2 rgp120
Number of subjects: 49
Study 9573498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy with lisinopril
Number of subjects: 3164
Study 9573498 — intervention group
Group type: COMPARATOR
Intervention: Low-dose therapy with lisinopril
Number of subjects: 3164
Study 9573498 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use variation
Number of subjects: 3164
Study 7923519 — intervention group
Group type: EXPERIMENTAL
Intervention: One-lung ventilation (OLV)
Number of subjects: 30
Study 7923519 — intervention group
Group type: COMPARATOR
Intervention: Two-lung ventilation (TLV)
Number of subjects: 30
Study 3408038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (loading dose 0.5 mg.kg‐1 followed by infusion of 5 micrograms.kg‐1.min‐1)
Number of subjects: 66
Study 3408038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 3408038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 66
Study 3408038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and Placebo
Number of subjects: 66